Skip to content

H2020FP7HORIZON

Heinrich-Heine-Universitaet Duesseldorf

Country
DEGermany
Defence projects
0
Projects, all programmes
158
As coordinator
49
EU contribution (CORDIS)
EUR 85,713,032
Active
2008 to 2026

Projects

158 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
BACTBioactive compounds from Turkish marine macro organism and associated fungi for EU industriesFP72013ParticipantEUR 39,900
HBPThe Human Brain ProjectFP72013ParticipantEUR 318,708
OraModVPH based predictive model for oral cancer reoccurrence in the clinical practiceFP72013ParticipantEUR 304,562
BIOMEDBRIDGESBuilding data bridges between biological and medical infrastructures in EuropeFP72012ParticipantEUR 931,611
EVOLATERALThe mechanisms for lateral gene transfer in nature as reflected in prokaryote genomesFP72012ParticipantEUR 84,493
ABIRISKAnti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the riskFP72012ParticipantEUR 536,525
CTCTRAPCirculating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patientsFP72012ParticipantEUR 386,250
DRIVERSDRIVERS: Addressing the strategic Determinants to Reduce health Inequality Via 1) Early childhood development, 2) Realising fair employment, and 3) Social protectionFP72012ParticipantEUR 392,120
ECRIN-IAEuropean Clinical Research Infrastructures Network - Integrating ActivityFP72012ParticipantEUR 210,273
3TO43to4: Converting C3 to C4 photosynthesis for sustainable agricultureFP72012ParticipantEUR 1,460,120
EPITRAITSEpigenetic regulation of economically important plant traitsFP72012ParticipantEUR 203,445
BEHAVIORAL THEORYBehavioral Theory and Economic ApplicationsFP72012ParticipantEUR 81,249
ACCLIPHOTEnvironmental Acclimation of PhotosynthesisFP72012CoordinatorEUR 772,812
TRANSDOTTTRANSLATION OF DOMESTICATION OF THUNNUS THYNNUS INTO AN INNOVATIVE COMMERCIAL APPLICATIONFP72012CoordinatorEUR 95,456
IMPACTTImmunoglobulin IgY pseudomonas A clinical trial for cystic fibrosis treatmentFP72011ParticipantEUR 625,900
TINN2Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonatesFP72011ParticipantEUR 25,000
SOC2Towards Neutral-atom Space Optical Clocks: Development of high-performance transportable and breadboard optical clocks and advanced subsystemsFP72011CoordinatorEUR 392,000
ADVANCEAdvanced Design and Verification Environment for Cyber-physical System EngineeringFP72011ParticipantEUR 513,310
p-medicineFrom data sharing and integration via VPH models to personalised medicineFP72011ParticipantEUR 526,311
EHR4CRElectronic Health Record systems for Clinical ResearchFP72011ParticipantEUR 412,500

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.